Companies › ALGS
Aligos Therapeutics Inc (ALGS)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001799448 · EDGAR filings · Updated 2026-06-29
Aligos Therapeutics Inc (ALGS) has reported institutional ownership of 44.8%, with 34 institutional managers holding positions valued at $20.6M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-06-29 — Insider transaction reported (Form 4)
- 2026-06-29 — Insider transaction reported (Form 4)
- 2026-06-29 — Insider transaction reported (Form 4)
- 2026-06-29 — Insider transaction reported (Form 4)
- 2026-06-29 — Insider transaction reported (Form 4)
- 2026-06-29 — Insider transaction reported (Form 4)
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, Aligos Therapeutics Inc has 34 institutional holders and institutional ownership of 44.8%.
Insider activity
Insiders reported 0 transactions (0 buys, 0 sells) across 0 reporting insiders, with a net reported value of $0.
Data flags from SEC filings
Related companies
Black Hawk Acquisition Corp (BKHA) · ACRIVON THERAPEUTICS INC (ACRV) · ALPHA TEKNOVA INC (TKNO) · BIOTE CORP (BTMD) · Seres Therapeutics Inc (MCRB) · Neonc Technologies HLDGS (NTHI)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-29.